Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice - Advances in Bioscience and Biotechnology

ABB > Vol.4 No.2, February 2013

Advances in Bioscience and Biotechnology

Volume 4, Issue 2 (February 2013)

ISSN Print: 2156-8456 ISSN Online: 2156-8502

Google-based Impact Factor: 1.18 Citations h5-index & Ranking

Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice ()

HTML XML

Download as PDF (Size: 1129KB) PP. 153-163

DOI: 10.4236/abb.2013.42023 5,286 Downloads 8,737 Views Citations

Author(s)

Somdet Srichairatanakool, Kanjana Pangjit, Chada Phisalaphong, Suthat Fucharoen

Affiliation(s)

Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Institute of Research and Development, Government Pharmaceutical Organization, Ministry of Public Health, Bangkok, Thailand.
Thalassemia Research Center, Institute of Molecular Bioscience, Mahidol University Salaya Campus, Nakornpathom, Thailand.

ABSTRACT

Desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) are promising effective iron chelators for the treatment of iron overload in b-thalassemia patients; nonetheless, their side effects have also been reported. 3-Hydroxypyridinone derivatives are being developed as a safer new chelator and in combined chelation therapy. We evaluated the iron-chelating activity of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) in iron-loaded C57BL6 mice. The feeding of a ferrocene-supplemented diet (Fe diet) to mice resulted in iron overload, detectable plasma nontransferrin-bound iron (NTBI) and labile plasma iron (LPI), and increases of red cell membrane iron, plasma malondialdehyde (MDA) and excessive tissue iron deposits. Like DFP, the CM1 lowered the levels of the membrane non-heme iron, the NTBI and LPI (p < 0.05) and the MDA after 3 months of treatment. Administration of the Fe diet and the Fe diet along with the chelators did not change the morphology of the liver and heart. Numerous iron accumulations were observed in the liver and spleen tissues of the Fe dietfed mice, whereas the CM1 reduced such iron deposition. Thus, 1-(N-acetyl-6-aminohexyl)-3-hydro- xypyridin-4-one (CM1) can be considered a candidate bidentate oral iron chelator and is effective in the removal of toxic irons in blood compartment and tissues. The effectiveness and toxicity of the CM1 need to be investigated extensively in thalassemia mice and patients with iron overload.

KEYWORDS

Thalassemia; Iron Overload; Iron Chelator; Hydroxypyridinone; Lipid Peroxidation; Malondialdehyde

Share and Cite:

Srichairatanakool, S. , Pangjit, K. , Phisalaphong, C. and Fucharoen, S. (2013) Evaluation of a novel oral iron chelator 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) for treatment of iron overload in mice. Advances in Bioscience and Biotechnology, 4, 153-163. doi: 10.4236/abb.2013.42023.

Cited by

[1]	Protection of Iron-Induced Oxidative Damage in Neuroblastoma (SH-SY5Y) Cells by Combination of 1-(N-Acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4 …
	2021

[2]	Special Issue on Nano-Biointerface for Biosensing
	Applied Sciences, 2019

[3]	INNOVATIVE POLYMERIC IRON CHELATORS WITH HIGH IRON BINDING AFFINITY AND BIOCOMPATIBILITY FOR THE TREATMENT OF …
	2015

[4]	Molecular characterization of Beta-thalassemia Mutations in Holy Karbala
	2015

[5]	Polymeric nanocarriers for the treatment of systemic iron overload
	Molecular and Cellular Therapies, 2015

[6]	Innovative polymeric iron chelators with iron binding affinity and biocompatibility for the treatment of transfusional iron overload.
	2015

[7]	Role of Iron Chelation Therapy for Beta-Thalassemia Major: A Review
	2014

[8]	Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β- …
	Asian Pacific Journal of Tropical Biomedicine, 2014

[9]	Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β …
	Asian Pacific Journal of Tropical Biomedicine, 2014

[10]	Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and …
	Experimental and Toxicologic Pathology, 2014

[11]	Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β-thalassemic mice
	Asian Pacific journal of tropical biomedicine, 2014

[12]	Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone
	Experimental and Toxicologic Pathology, 2014

[13]	Recent developments centered on orally active iron chelators
	Thalassemia Reports, 2014

[14]	Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice
	Asian Pacific journal of tropical medicine, 2014

[15]	Toxicity study of a novel oral iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in transgenic b-thalassemia mice
	Vitam Miner, 2013

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies